Navigation Links
Biocartis Presents the Successful use of Idylla[TM] for the Detection of the BRAF Mutation Status in Tumour Samples at the International AACR Congress (American Association for Cancer Research) in Boston

MECHELEN, Belgium and LAUSANNE, Switzerland, October 22, 2013 /PRNewswire/ --

Biocartis also introduces IdyllaTM, the brand name for its innovative and high-quality diagnostic platform (previously codenamed Apollo). IdyllaTM is designed to carry out fast and accurate analysis of a broad range of clinical samples[1]. The platform retains the sensitivity of existing technologies but overcomes, amongst others, the current time-consuming testing process of tumour samples.

Apollo becomes IdyllaTM

IdyllaTM is Biocartis' commercial brand name for the fully integrated molecular diagnostic platform, which analyses clinical samples accurately, fast and easily. It gives short shrift to today's time-consuming molecular testing processes. IdyllaTM will provide a direct access to a wide array of tests in various diagnostic areas. Biocartis is currently developing tests primarily in the field of oncology.

Fast and accurate analysis of tumour samples

In collaboration with the world-renowned American MD Anderson Cancer Center, IdyllaTM was used in a comparative study that included various tumour types, for the presence of the BRAF cancer gene.

Today, Dr Janku from MD Anderson and Biocartis presented the results from this study at the international congress of the American Association for Cancer Research AACR-NCI-EORTC (Molecular Targets and Cancer Therapeutics). At this conference, the latest innovations in cancer diagnosis are presented to a large delegation of cancer experts from both the research and clinical/pharmaceutical world. The study was also selected by AACR as one of three studies presented at the AACR press conference today:

IdyllaTM simply and rapidly detects mutations and shows a much higher sensitivity as compared to standard diagnostic assays and standard sequencing, thereby eliminating the need for dissection of the tumor region. These technologies are available in highly specialised laboratories, where the process from sample to result can take several weeks, whilst IdyllaTM yields a reportable result in 35-90 minutes, depending on the test.

IdyllaTM and first cancer test on the market in second half of 2014

IdyllaTM and the BRAF test will be marketed by Biocartis. The launch of the platform and the BRAF assay in Europe is expected in the second half of 2014.

About Biocartis (

Biocartis aspires to improve quality of life by providing direct access to personalized medicine to patients worldwide. Its goal is to advance medical treatment through the broad implementation of state-of-the-art personalized diagnostic tests performed close to the clinical decision-making point.

Biocartis' innovative research and diagnostic systems feature the detection of molecular components, which are indicative for a specific pathological state. The new systems are highly user-friendly, require less hands-on time and minimize the handling of valuable samples, which is of the utmost importance for tumor biopsies. In addition, Biocartis develops assays with major clinical and compelling health economic value. Oncology is Biocartis' primary focus as it represents one of the areas with the greatest unmet needs for personalized medicine.

Biocartis is a rapidly growing business that currently employs close to 200 people. It has offices in Belgium (close to Brussels) and in Switzerland (Lausanne).

[1] Platform and assays are currently under development. For Research Use Only. Not for use in diagnostic procedures.

SOURCE Biocartis
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biocartis Strengthens Management Team With Chief Commercial Officer
2. Biocartis versterkt managementteam met commercieel directeur
3. 3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
4. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
5. Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At The World Parkinsons Congress
6. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
7. Prolong Pharmaceuticals Presents Novel Multi-Pronged Approach To Treating Sickle Cell Disease At The SCDAA Meeting
8. ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naive Adults with HIV-1
9. Metabolic Solutions Development Company presents Phase 2a clinical trial results at the 14th International Conference on Alzheimers Drug Discovery
10. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
11. ARUP Laboratories Presents Recent Findings at PAINWeek
Post Your Comments:
(Date:11/25/2015)... , Nov. 26, 2015  The total global healthcare ... 7% over 2015-2016. Latin America has ... , (excluding Japan ), is second ... continues to face increased healthcare expenditure. In 2013-2014, total ... declined from 43.5% in 2008-2009 to 41.2% in 2013-2014. In ...
(Date:11/25/2015)... 2015 AAIPharma Services Corp./Cambridge Major Laboratories, ... least $15.8  Million to expand its laboratories and ... . The expansion will provide additional office space ... demands of the pharmaceutical and biotechnology markets. ... provide up to 40,000 square feet of expanded ...
(Date:11/25/2015)... Israel , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused ... treatment of various clinical conditions, today announced the closing ... American Depository Shares ( ADSs ), each representing 20 ... up to 3,158,900 ADSs. The ADSs and warrants were ...
Breaking Medicine Technology:
(Date:11/26/2015)... Toronto, ON and Cambridge, ON (PRWEB) , ... ... ... announced today the availability of a real-time eReferral system for diagnostic imaging in ... CTs, ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating ... our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment ... day excited to rebuild lives and it’s an honor to have served all of ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center ... reliability. , The new Q-Suite 6 platform is based on the latest Java Enterprise ... a specific piece of software for many key components of the suite. Much of ...
Breaking Medicine News(10 mins):